Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication May 5, 2021
- Accepted for publication July 7, 2021
- Published online October 1, 2021.
Article Versions
- previous version (July 16, 2021 - 12:50).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Jeremie Calais1–3,
- Johannes Czernin1–3,*,
- Pan Thin1,
- Jeannine Gartmann1,
- Kathleen Nguyen1,
- Wesley R. Armstrong1,
- Martin Allen-Auerbach1–3,
- Andrew Quon1–3,
- Shadfar Bahri1–3,
- Pawan Gupta1,
- Linda Gardner1,
- Magnus Dahlbom1,
- Beilei He4,
- Rouzbeh Esfandiari5,
- David Ranganathan6,
- Ken Herrmann7,
- Matthias Eiber8,
- Wolfgang P. Fendler7 and
- Ebrahim Delpassand5,6,*
- 1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
- 2Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California;
- 3Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California;
- 4Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland;
- 5Excel Diagnostics and Nuclear Oncology Center, Houston, Texas;
- 6RadioMedix, Inc., Houston, Texas;
- 7Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; and
- 8Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany
- For correspondence or reprints, contact Jeremie Calais (jcalais{at}mednet.ucla.edu). Guest Editor: Todd Peterson, Vanderbilt University. *Contributed equally to this work.
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy
- Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience
- Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy
- Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression
- Pathway to Approval of Innovative Radiopharmaceuticals in China
- Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
- Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation
- A 2022 International Survey on the Status of Prostate Cancer Theranostics
- From Concept to Regulatory Drug Approval: Lessons for Theranostics